Exenatide has potential as disease modifying agent in Parkinson's disease
- Tue 06 May 2014 01:48:PM
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers.
Source: Exenatide has potential as disease modifying agent in Parkinson's disease
Source: Exenatide has potential as disease modifying agent in Parkinson's disease